{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:58:43Z","timestamp":1793944723734,"version":"4.8.0"},"reference-count":169,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Endocrinol"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1038\/s41574-024-01083-8","type":"journal-article","created":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T11:33:09Z","timestamp":1737027189000},"page":"301-313","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["The effects of type 1 and type 2 diabetes mellitus on bone health in chronic kidney disease"],"prefix":"10.1038","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0443-7165","authenticated-orcid":false,"given":"Jasna","family":"Aleksova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2921-3742","authenticated-orcid":false,"given":"Peter","family":"Ebeling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5685-4636","authenticated-orcid":false,"given":"Grahame","family":"Elder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,16]]},"reference":[{"key":"1083_CR1","doi-asserted-by":"crossref","first-page":"109119","DOI":"10.1016\/j.diabres.2021.109119","volume":"183","author":"H Sun","year":"2022","unstructured":"Sun, H. et al. IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res. Clin. Pract. 183, 109119 (2022).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"1083_CR2","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s00198-015-3279-7","volume":"27","author":"Y Fan","year":"2016","unstructured":"Fan, Y., Wei, F., Lang, Y. & Liu, Y. Diabetes mellitus and risk of hip fractures: a meta-analysis. Osteoporos. Int. 27, 219\u2013228 (2016).","journal-title":"Osteoporos. Int."},{"key":"1083_CR3","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00198-006-0253-4","volume":"18","author":"P Vestergaard","year":"2007","unstructured":"Vestergaard, P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes \u2013 a meta-analysis. Osteoporos. Int. 18, 427\u2013444 (2007).","journal-title":"Osteoporos. Int."},{"key":"1083_CR4","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s40520-016-0562-1","volume":"29","author":"J Dytfeld","year":"2017","unstructured":"Dytfeld, J. & Michalak, M. Type 2 diabetes and risk of low-energy fractures in postmenopausal women: meta-analysis of observational studies. Aging Clin. Exp. Res. 29, 301\u2013309 (2017).","journal-title":"Aging Clin. Exp. Res."},{"key":"1083_CR5","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1359\/jbmr.081207","volume":"24","author":"M Yamamoto","year":"2009","unstructured":"Yamamoto, M., Yamaguchi, T., Yamauchi, M., Kaji, H. & Sugimoto, T. Diabetic patients have an increased risk of vertebral fractures independent of BMD or diabetic complications. J. Bone Miner. Res. 24, 702\u2013709 (2009).","journal-title":"J. Bone Miner. Res."},{"key":"1083_CR6","doi-asserted-by":"crossref","first-page":"455","DOI":"10.2147\/TCRM.S131945","volume":"13","author":"A Moayeri","year":"2017","unstructured":"Moayeri, A. et al. Fracture risk in patients with type 2 diabetes mellitus and possible risk factors: a systematic review and meta-analysis. Ther. Clin. Risk Manag. 13, 455\u2013468 (2017).","journal-title":"Ther. Clin. Risk Manag."},{"key":"1083_CR7","doi-asserted-by":"crossref","first-page":"115457","DOI":"10.1016\/j.bone.2020.115457","volume":"137","author":"T Vilaca","year":"2020","unstructured":"Vilaca, T. et al. The risk of hip and non-vertebral fractures in type 1 and type 2 diabetes: a systematic review and meta-analysis update. Bone 137, 115457 (2020).","journal-title":"Bone"},{"key":"1083_CR8","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/aje\/kwm106","volume":"166","author":"M Janghorbani","year":"2007","unstructured":"Janghorbani, M., Van Dam, R. M., Willett, W. C. & Hu, F. B. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am. J. Epidemiol. 166, 495\u2013505 (2007).","journal-title":"Am. J. Epidemiol."},{"key":"1083_CR9","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.bone.2015.05.032","volume":"82","author":"AV Schwartz","year":"2016","unstructured":"Schwartz, A. V. Epidemiology of fractures in type 2 diabetes. Bone 82, 2\u20138 (2016).","journal-title":"Bone"},{"key":"1083_CR10","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.2337\/dc15-0783","volume":"38","author":"DR Weber","year":"2015","unstructured":"Weber, D. R., Haynes, K., Leonard, M. B., Willi, S. M. & Denburg, M. R. Type 1 diabetes is associated with an increased risk of fracture across the life span: a population-based cohort study using The Health Improvement Network (THIN). Diabetes Care 38, 1913\u20131920 (2015).","journal-title":"Diabetes Care"},{"key":"1083_CR11","doi-asserted-by":"crossref","first-page":"e1390","DOI":"10.1210\/clinem\/dgab882","volume":"107","author":"B Wang","year":"2022","unstructured":"Wang, B. et al. Unmasking fracture risk in type 2 diabetes: the association of longitudinal glycemic hemoglobin level and medications. J. Clin. Endocrinol. Metab. 107, e1390\u2013e1401 (2022).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1083_CR12","doi-asserted-by":"publisher","unstructured":"Draghici, A. E., Zahedi, B., Taylor, J. A., Bouxsein, M. L. & Yu, E. W. Vascular deficits contributing to skeletal fragility in type 1 diabetes. Front. Clin. Diabetes Healthcare 4, https:\/\/doi.org\/10.3389\/fcdhc.2023.1272804 (2023).","DOI":"10.3389\/fcdhc.2023.1272804"},{"key":"1083_CR13","doi-asserted-by":"crossref","unstructured":"Elger, M., Parpia, A. S. & Whitham, D. in Nutrition in Kidney Disease (eds Burrowes J. D., Kovesdy, C. P. & Byham-Gray L. D.) 175\u2013196 (Springer, 2020).","DOI":"10.1007\/978-3-030-44858-5_11"},{"key":"1083_CR14","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.kint.2017.04.006","volume":"92","author":"M Ketteler","year":"2017","unstructured":"Ketteler, M. et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease\u2013Mineral and Bone Disorder (CKD-MBD) Guideline Update: what\u2019s changed and why it matters. Kidney Int. 92, 26\u201336 (2017).","journal-title":"Kidney Int."},{"key":"1083_CR15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0271555","volume":"17","author":"HH Malluche","year":"2022","unstructured":"Malluche, H. H., Davenport, D. L., Lima, F. & Monier-Faugere, M. C. Prevalence of low bone formation in untreated patients with osteoporosis. PLoS ONE 17, e0271555 (2022).","journal-title":"PLoS ONE"},{"key":"1083_CR16","doi-asserted-by":"crossref","first-page":"R137","DOI":"10.1530\/EJE-16-0652","volume":"176","author":"K Hygum","year":"2017","unstructured":"Hygum, K., Starup-Linde, J., Harslof, T., Vestergaard, P. & Langdahl, B. L. Mechanisms in endocrinology: diabetes mellitus, a state of low bone turnover \u2013 a systematic review and meta-analysis. Eur. J. Endocrinol. 176, R137\u2013R157 (2017).","journal-title":"Eur. J. Endocrinol."},{"key":"1083_CR17","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/jbmr.1763","volume":"28","author":"JM Patsch","year":"2013","unstructured":"Patsch, J. M. et al. Increased cortical porosity in type 2 diabetic postmenopausal women with fragility fractures. J. Bone Miner. Res. 28, 313\u2013324 (2013).","journal-title":"J. Bone Miner. Res."},{"key":"1083_CR18","doi-asserted-by":"crossref","first-page":"e923","DOI":"10.1210\/clinem\/dgad255","volume":"108","author":"C Meier","year":"2023","unstructured":"Meier, C. et al. Biochemical markers of bone fragility in patients with diabetes. J. Clin. Endocrinol. Metab.\u00a0108, e923\u2013e936 (2023).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1083_CR19","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/jbmr.4757","volume":"38","author":"S Lekkala","year":"2023","unstructured":"Lekkala, S. et al. Increased advanced glycation endproducts, stiffness, and hardness in iliac crest bone from postmenopausal women with type 2 diabetes mellitus on insulin. J. Bone Miner. Res. 38, 261\u2013277 (2023).","journal-title":"J. Bone Miner. Res."},{"key":"1083_CR20","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.bone.2003.07.005","volume":"33","author":"K Stenderup","year":"2003","unstructured":"Stenderup, K., Justesen, J., Clausen, C. & Kassem, M. Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells. Bone 33, 919\u2013926 (2003).","journal-title":"Bone"},{"key":"1083_CR21","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1002\/jbmr.4153","volume":"35","author":"A Piccoli","year":"2020","unstructured":"Piccoli, A. et al. Sclerostin regulation, microarchitecture, and advanced glycation end-products in the bone of elderly women with type 2 diabetes. J. Bone Miner. Res. 35, 2415\u20132422 (2020).","journal-title":"J. Bone Miner. Res."},{"key":"1083_CR22","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.2337\/diacare.28.12.2850","volume":"28","author":"J Miao","year":"2005","unstructured":"Miao, J., Brismar, K., Nyr\u00e9n, O., Ugarph-Morawski, A. & Ye, W. Elevated hip fracture risk in type 1 diabetic patients: a population-based cohort study in Sweden. Diabetes Care 28, 2850\u20132855 (2005).","journal-title":"Diabetes Care"},{"key":"1083_CR23","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1002\/jbmr.2573","volume":"30","author":"VV Shanbhogue","year":"2015","unstructured":"Shanbhogue, V. V. et al. Bone geometry, volumetric density, microarchitecture, and estimated bone strength assessed by HR-pQCT in adult patients with type 1 diabetes mellitus. J. Bone Miner. Res. 30, 2188\u20132199 (2015).","journal-title":"J. Bone Miner. Res."},{"key":"1083_CR24","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/8756-3282(93)90092-O","volume":"14","author":"H Brockstedt","year":"1993","unstructured":"Brockstedt, H., Kassem, M., Eriksen, E. F., Mosekilde, L. & Melsen, F. Age- and sex-related changes in iliac cortical bone mass and remodeling. Bone 14, 681\u2013691 (1993).","journal-title":"Bone"},{"key":"1083_CR25","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.bone.2019.03.039","volume":"123","author":"VN Shah","year":"2019","unstructured":"Shah, V. N. et al. Type 1 diabetes onset at young age is associated with compromised bone quality. Bone 123, 260\u2013264 (2019).","journal-title":"Bone"},{"key":"1083_CR26","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1007\/s00198-015-3440-3","volume":"27","author":"CM Weaver","year":"2016","unstructured":"Weaver, C. M. et al. The National Osteoporosis Foundation\u2019s position statement on peak bone mass development and lifestyle factors: a systematic review and implementation recommendations. Osteoporos. Int. 27, 1281\u20131386 (2016).","journal-title":"Osteoporos. Int."},{"key":"1083_CR27","volume":"6","author":"JJ Cao","year":"2011","unstructured":"Cao, J. J. Effects of obesity on bone metabolism. J. Orthop. Surg. Res. 6, 30 (2011).","journal-title":"J. Orthop. Surg. Res."},{"key":"1083_CR28","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1477-7827-9-61","volume":"9","author":"BM Schweiger","year":"2011","unstructured":"Schweiger, B. M., Snell-Bergeon, J. K., Roman, R., McFann, K. & Klingensmith, G. J. Menarche delay and menstrual irregularities persist in adolescents with type 1 diabetes. Reprod. Biol. Endocrinol. : RBE 9, 61 (2011).","journal-title":"Reprod. Biol. Endocrinol. : RBE"},{"key":"1083_CR29","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jpag.2009.06.006","volume":"23","author":"A Deltsidou","year":"2010","unstructured":"Deltsidou, A. Age at menarche and menstrual irregularities of adolescents with type 1 diabetes. J. Pediatr. Adolesc. Gynecol. 23, 162\u2013167 (2010).","journal-title":"J. Pediatr. Adolesc. Gynecol."},{"key":"1083_CR30","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/cen.13488","volume":"88","author":"EP Thong","year":"2018","unstructured":"Thong, E. P. et al. Increased prevalence of fracture and hypoglycaemia in young adults with concomitant type 1 diabetes mellitus and coeliac disease. Clin. Endocrinol. 88, 37\u201343 (2018).","journal-title":"Clin. Endocrinol."},{"key":"1083_CR31","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ecl.2013.09.010","volume":"43","author":"J Mitri","year":"2014","unstructured":"Mitri, J. & Pittas, A. G. Vitamin D and diabetes. Endocrinol. Metab. Clin. North. Am. 43, 205\u2013232 (2014).","journal-title":"Endocrinol. Metab. Clin. North. Am."},{"key":"1083_CR32","first-page":"8414689","volume":"2024","author":"X He","year":"2024","unstructured":"He, X. et al. Parathyroid hormone is negatively correlated with glycated hemoglobin in newly diagnosed type 2 diabetic patients. Int. J. Endocrinol. 2024, 8414689 (2024).","journal-title":"Int. J. Endocrinol."},{"key":"1083_CR33","unstructured":"ANZDATA Registry. Prevalence of Kidney Failure with Replacement Therapy. 44th Report, Chapter 2. Australia and New Zealand Dialysis and Transplant Registry https:\/\/www.anzdata.org.au\/wp-content\/uploads\/2021\/09\/c02_prevalence_2020_ar_2021_chapter_v1.0_20211112_Final.pdf (2021)."},{"key":"1083_CR34","volume":"2","author":"Y Asamiya","year":"2016","unstructured":"Asamiya, Y., Tsuchiya, K. & Nitta, K. Role of sclerostin in the pathogenesis of chronic kidney disease-mineral bone disorder. Ren. Replacement Ther. 2, 8 (2016).","journal-title":"Ren. Replacement Ther."},{"key":"1083_CR35","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1177\/1759720X13510479","volume":"6","author":"EM Lewiecki","year":"2014","unstructured":"Lewiecki, E. M. Role of sclerostin in bone and cartilage and its potential as a therapeutic target in bone diseases. Ther. Adv. Musculoskelet. Dis. 6, 48\u201357 (2014).","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"1083_CR36","doi-asserted-by":"crossref","first-page":"646","DOI":"10.2215\/CJN.06040614","volume":"10","author":"KL Naylor","year":"2015","unstructured":"Naylor, K. L. et al. Comparison of fracture risk prediction among individuals with reduced and normal kidney function. Clin. J. Am. Soc. Nephrol. 10, 646\u2013653 (2015).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1083_CR37","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/ki.2013.547","volume":"86","author":"KL Naylor","year":"2014","unstructured":"Naylor, K. L. et al. The three-year incidence of fracture in chronic kidney disease. Kidney Int. 86, 810\u2013818 (2014).","journal-title":"Kidney Int."},{"key":"1083_CR38","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/ki.2013.279","volume":"85","author":"F Tentori","year":"2014","unstructured":"Tentori, F. et al. High rates of death and hospitalization follow bone fracture among hemodialysis patients. Kidney Int. 85, 166\u2013173 (2014).","journal-title":"Kidney Int."},{"key":"1083_CR39","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal, B., Perkovic, V. & Matthews, D. R. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N. Engl. J. Med. 377, 2099 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1083_CR40","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic, V. et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N. Engl. J. Med. 380, 2295\u20132306 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1083_CR41","doi-asserted-by":"crossref","first-page":"9998891","DOI":"10.1155\/2022\/9998891","volume":"2022","author":"TK Young","year":"2022","unstructured":"Young, T. K. et al. Risk factors for fracture in patients with coexisting chronic kidney disease and type 2 diabetes: an observational analysis from the CREDENCE trial. J. Diabetes Res. 2022, 9998891 (2022).","journal-title":"J. Diabetes Res."},{"key":"1083_CR42","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1530\/EJE-22-0687","volume":"187","author":"J Aleksova","year":"2022","unstructured":"Aleksova, J., Ebeling, P., Milat, F. & Elder, G. DXA-derived advanced hip analysis and the trabecular bone score in end stage kidney disease secondary to type 1 diabetes. Eur. J. Endocrinol. 187, 883\u2013892 (2022).","journal-title":"Eur. J. Endocrinol."},{"key":"1083_CR43","doi-asserted-by":"crossref","first-page":"73","DOI":"10.5301\/jn.5000212","volume":"26","author":"JB Cannata-And\u00eda","year":"2013","unstructured":"Cannata-And\u00eda, J. B., Rodriguez Garc\u00eda, M. & G\u00f3mez Alonso, C. Osteoporosis and adynamic bone in chronic kidney disease. J. Nephrol. 26, 73\u201380 (2013).","journal-title":"J. Nephrol."},{"key":"1083_CR44","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/ki.1993.350","volume":"44","author":"AJ Hutchison","year":"1993","unstructured":"Hutchison, A. J. et al. Correlation of bone histology with parathyroid hormone, vitamin D3, and radiology in end-stage renal disease. Kidney Int. 44, 1071\u20131077 (1993).","journal-title":"Kidney Int."},{"key":"1083_CR45","first-page":"22","volume":"105","author":"JM Modest","year":"2022","unstructured":"Modest, J. M., Sheth, H., Gohh, R. & Aaron, R. K. Osteomalacia and renal osteodystrophy. Rhode Isl. Med. J. 105, 22\u201327 (2022).","journal-title":"Rhode Isl. Med. J."},{"key":"1083_CR46","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1681\/ASN.2006070771","volume":"18","author":"KJ Martin","year":"2007","unstructured":"Martin, K. J. & Gonz\u00e1lez, E. A. Metabolic bone disease in chronic kidney disease. J. Am. Soc. Nephrol. 18, 875\u2013885 (2007).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1083_CR47","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12882-023-03175-5","volume":"24","author":"M Elder","year":"2023","unstructured":"Elder, M. et al. Chronic kidney disease-related sarcopenia as a prognostic indicator in elderly haemodialysis patients. BMC Nephrol. 24, 138 (2023).","journal-title":"BMC Nephrol."},{"key":"1083_CR48","doi-asserted-by":"crossref","first-page":"e3718","DOI":"10.1210\/clinem\/dgaa388","volume":"105","author":"P Samakkarnthai","year":"2020","unstructured":"Samakkarnthai, P. et al. Determinants of bone material strength and cortical porosity in patients with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 105, e3718\u20133729 (2020).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1083_CR49","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1002\/jbmr.1916","volume":"28","author":"TL Nickolas","year":"2013","unstructured":"Nickolas, T. L. et al. Rapid cortical bone loss in patients with chronic kidney disease. J. Bone Miner. Res. 28, 1811\u20131820 (2013).","journal-title":"J. Bone Miner. Res."},{"key":"1083_CR50","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.bone.2018.05.029","volume":"114","author":"AK Sharma","year":"2018","unstructured":"Sharma, A. K. et al. Magnetic resonance imaging based assessment of bone microstructure as a non-invasive alternative to histomorphometry in patients with chronic kidney disease. Bone 114, 14\u201321 (2018).","journal-title":"Bone"},{"key":"1083_CR51","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1159\/000489671","volume":"47","author":"AK Sharma","year":"2018","unstructured":"Sharma, A. K. et al. Deterioration of cortical bone microarchitecture: critical component of renal osteodystrophy evaluation. Am. J. Nephrol. 47, 376\u2013384 (2018).","journal-title":"Am. J. Nephrol."},{"key":"1083_CR52","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/ndt\/gfz195","volume":"36","author":"J Aleksova","year":"2019","unstructured":"Aleksova, J. et al. Patients with end-stage kidney disease have markedly abnormal cortical hip parameters by dual-energy X-ray absorptiometry. Nephrol. Dial. Transplant. 36, 543\u2013550 (2019).","journal-title":"Nephrol. Dial. Transplant."},{"key":"1083_CR53","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.1210\/jc.2012-1546","volume":"97","author":"JS Manavalan","year":"2012","unstructured":"Manavalan, J. S. et al. Circulating osteogenic precursor cells in type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 97, 3240\u20133250 (2012).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1083_CR54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.kisu.2017.04.001","volume":"7","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group","year":"2017","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group KDIGO 2017 Clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease\u2013mineral and bone disorder (CKD-MBD). Kidney Int. Suppl. 7, 1\u201359 (2017).","journal-title":"Kidney Int. Suppl."},{"key":"1083_CR55","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/jbmr.2406","volume":"30","author":"SL West","year":"2015","unstructured":"West, S. L. et al. Bone mineral density predicts fractures in chronic kidney disease. J. Bone Miner. Res. 30, 913\u2013919 (2015).","journal-title":"J. Bone Miner. Res."},{"key":"1083_CR56","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/ndt\/gfr317","volume":"27","author":"S Iimori","year":"2012","unstructured":"Iimori, S. et al. Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients \u2013 a single-center cohort study. Nephrol. Dial. Transplant. 27, 345\u2013351 (2012).","journal-title":"Nephrol. Dial. Transplant."},{"key":"1083_CR57","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.bone.2015.05.016","volume":"78","author":"NC Harvey","year":"2015","unstructured":"Harvey, N. C. et al. Trabecular bone score (TBS) as a new complementary approach for osteoporosis evaluation in clinical practice. Bone 78, 216\u2013224 (2015).","journal-title":"Bone"},{"key":"1083_CR58","doi-asserted-by":"crossref","first-page":"228","DOI":"10.3899\/jrheum.140752","volume":"42","author":"E Koumakis","year":"2015","unstructured":"Koumakis, E. et al. Trabecular bone score in female patients with systemic sclerosis: comparison with rheumatoid arthritis and influence of glucocorticoid exposure. J. Rheumatol. 42, 228\u2013235 (2015).","journal-title":"J. Rheumatol."},{"key":"1083_CR59","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1210\/jc.2012-3118","volume":"98","author":"WD Leslie","year":"2013","unstructured":"Leslie, W. D., Aubry-Rozier, B., Lamy, O. & Hans, D. Manitoba Bone Density Program TBS (trabecular bone score) and diabetes-related fracture risk. J. Clin. Endocrinol. Metab. 98, 602\u2013609 (2013).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1083_CR60","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jocd.2016.11.002","volume":"20","author":"MP Yavropoulou","year":"2016","unstructured":"Yavropoulou, M. P. et al. Bone quality assessment as measured by trabecular bone score in patients with end-stage renal disease on dialysis. J. Clin. Densitom. 20, 490\u2013497 (2016).","journal-title":"J. Clin. Densitom."},{"key":"1083_CR61","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1007\/s00198-018-4468-y","volume":"29","author":"J Aleksova","year":"2018","unstructured":"Aleksova, J., Kurniawan, S. & Elder, G. J. The trabecular bone score is associated with bone mineral density, markers of bone turnover and prevalent fracture in patients with end stage kidney disease. Osteoporos. Int. 29, 1447\u20131455 (2018).","journal-title":"Osteoporos. Int."},{"key":"1083_CR62","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00198-015-3424-3","volume":"27","author":"KL Naylor","year":"2016","unstructured":"Naylor, K. L. et al. Trabecular bone score in kidney transplant recipients. Osteoporos. Int. 27, 1115\u20131121 (2016).","journal-title":"Osteoporos. Int."},{"key":"1083_CR63","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1359\/jbmr.080802","volume":"23","author":"S Kaptoge","year":"2008","unstructured":"Kaptoge, S. et al. Prediction of incident hip fracture risk by femur geometry variables measured by hip structural analysis in the study of osteoporotic fractures. J. Bone Miner. Res. 23, 1892\u20131904 (2008).","journal-title":"J. Bone Miner. Res."},{"key":"1083_CR64","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1007\/s00198-012-1908-y","volume":"23","author":"SA Jamal","year":"2012","unstructured":"Jamal, S. A., Cheung, A. M., West, S. L. & Lok, C. E. Bone mineral density by DXA and HR pQCT can discriminate fracture status in men and women with stages 3 to 5 chronic kidney disease. Osteoporos. Int. 23, 2805\u20132813 (2012).","journal-title":"Osteoporos. Int."},{"key":"1083_CR65","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/jbmr.2106","volume":"29","author":"JN Farr","year":"2014","unstructured":"Farr, J. N. et al. In vivo assessment of bone quality in postmenopausal women with type 2 diabetes. J. Bone Miner. Res. 29, 787\u2013795 (2014).","journal-title":"J. Bone Miner. Res."},{"key":"1083_CR66","doi-asserted-by":"crossref","first-page":"e2405","DOI":"10.1210\/clinem\/dgac099","volume":"107","author":"MR Rubin","year":"2022","unstructured":"Rubin, M. R. et al. Biochemical markers of bone turnover in older adults with type 1 diabetes. J. Clin. Endocrinol. Metab. 107, e2405\u2013e2416 (2022).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1083_CR67","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.2337\/dc23-0839","volume":"47","author":"N Sinha Gregory","year":"2023","unstructured":"Sinha Gregory, N. et al. Diabetes risk factors and bone microarchitecture as assessed by high-resolution peripheral quantitative computed tomography in adults with long-standing type 1 diabetes. Diabetes Care 47, 1548\u20131558 (2023).","journal-title":"Diabetes Care"},{"key":"1083_CR68","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1053\/j.ajkd.2015.06.023","volume":"67","author":"SM Sprague","year":"2016","unstructured":"Sprague, S. M. et al. Diagnostic accuracy of bone turnover markers and bone histology in patients with CKD treated by dialysis. Am. J. Kidney Dis. 67, 559\u2013566 (2016).","journal-title":"Am. J. Kidney Dis."},{"key":"1083_CR69","doi-asserted-by":"crossref","first-page":"381","DOI":"10.3343\/alm.2017.37.5.381","volume":"37","author":"Y Einbinder","year":"2017","unstructured":"Einbinder, Y., Benchetrit, S., Golan, E. & Zitman-Gal, T. Comparison of intact PTH and bio-intact PTH assays among non-dialysis dependent chronic kidney disease patients. Ann. Lab. Med. 37, 381\u2013387 (2017).","journal-title":"Ann. Lab. Med."},{"key":"1083_CR70","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/sj.ki.5002800","volume":"73","author":"TB Dr\u00fceke","year":"2008","unstructured":"Dr\u00fceke, T. B. Is parathyroid hormone measurement useful for the diagnosis of renal bone disease? Kidney Int. 73, 674\u2013676 (2008).","journal-title":"Kidney Int."},{"key":"1083_CR71","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.kint.2018.09.022","volume":"95","author":"RH Whitlock","year":"2018","unstructured":"Whitlock, R. H. et al. The Fracture Risk Assessment Tool (FRAX(R)) predicts fracture risk in patients with chronic kidney disease. Kidney Int. 95, 447\u2013454 (2018).","journal-title":"Kidney Int."},{"key":"1083_CR72","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s00198-018-4406-z","volume":"29","author":"J Przedlacki","year":"2018","unstructured":"Przedlacki, J. et al. The utility of FRAX(R) in predicting bone fractures in patients with chronic kidney disease on hemodialysis: a two-year prospective multicenter cohort study. Osteoporos. Int. 29, 1105\u20131115 (2018).","journal-title":"Osteoporos. Int."},{"key":"1083_CR73","doi-asserted-by":"crossref","first-page":"115188","DOI":"10.1016\/j.bone.2019.115188","volume":"133","author":"J Przedlacki","year":"2020","unstructured":"Przedlacki, J. et al. FRAX prognostic and intervention thresholds in the management of major bone fractures in hemodialysis patients: a two-year prospective multicenter cohort study. Bone 133, 115188 (2020).","journal-title":"Bone"},{"key":"1083_CR74","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1001\/jama.2011.715","volume":"305","author":"AV Schwartz","year":"2011","unstructured":"Schwartz, A. V. et al. Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. JAMA 305, 2184\u20132192 (2011).","journal-title":"JAMA"},{"key":"1083_CR75","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1002\/jbmr.3538","volume":"33","author":"WD Leslie","year":"2018","unstructured":"Leslie, W. D. et al. Comparison of methods for improving fracture risk assessment in diabetes: the Manitoba BMD Registry. J. Bone Miner. Res. 33, 1923\u20131930 (2018).","journal-title":"J. Bone Miner. Res."},{"key":"1083_CR76","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.diabres.2016.03.009","volume":"115","author":"BN Conway","year":"2016","unstructured":"Conway, B. N., Long, D. M., Figaro, M. K. & May, M. E. Glycemic control and fracture risk in elderly patients with diabetes. Diabetes Res. Clin. Pract. 115, 47\u201353 (2016).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"1083_CR77","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1210\/en.2015-1690","volume":"157","author":"G Xi","year":"2016","unstructured":"Xi, G., Rosen, C. J. & Clemmons, D. R. IGF-I and IGFBP-2 stimulate AMPK activation and autophagy, which are required for osteoblast differentiation. Endocrinology 157, 268\u2013281 (2016).","journal-title":"Endocrinology"},{"key":"1083_CR78","doi-asserted-by":"crossref","first-page":"391","DOI":"10.2337\/dc07-1152","volume":"31","author":"AV Schwartz","year":"2008","unstructured":"Schwartz, A. V. et al. Diabetes-related complications, glycemic control, and falls in older adults. Diabetes Care 31, 391\u2013396 (2008).","journal-title":"Diabetes Care"},{"key":"1083_CR79","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1007\/s00125-005-1786-3","volume":"48","author":"P Vestergaard","year":"2005","unstructured":"Vestergaard, P., Rejnmark, L. & Mosekilde, L. Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia 48, 1292\u20131299 (2005).","journal-title":"Diabetologia"},{"key":"1083_CR80","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3747\/pdi.2013.00344","volume":"34","author":"J Heaf","year":"2014","unstructured":"Heaf, J. Metformin in chronic kidney disease: time for a rethink. Perit. Dial. Int. 34, 353\u2013357 (2014).","journal-title":"Perit. Dial. Int."},{"key":"1083_CR81","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1002\/jcb.23206","volume":"112","author":"QG Mai","year":"2011","unstructured":"Mai, Q. G. et al. Metformin stimulates osteoprotegerin and reduces RANKL expression in osteoblasts and ovariectomized rats. J. Cell Biochem. 112, 2902\u20132909 (2011).","journal-title":"J. Cell Biochem."},{"key":"1083_CR82","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s00198-019-04948-1","volume":"30","author":"A Salari-Moghaddam","year":"2019","unstructured":"Salari-Moghaddam, A., Sadeghi, O., Keshteli, A. H., Larijani, B. & Esmaillzadeh, A. Metformin use and risk of fracture: a systematic review and meta-analysis of observational studies. Osteoporos. Int. 30, 1167\u20131173 (2019).","journal-title":"Osteoporos. Int."},{"key":"1083_CR83","first-page":"11","volume":"1","author":"A Sarkar","year":"2011","unstructured":"Sarkar, A., Tiwari, A., Bhasin, P. S. & Mitra, M. Pharmacological and pharmaceutical profile of gliclazide: a review. J. Appl. Pharm. Sci. 1, 11\u201319 (2011).","journal-title":"J. Appl. Pharm. Sci."},{"key":"1083_CR84","doi-asserted-by":"crossref","first-page":"S219","DOI":"10.2337\/dc24-S011","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2023","unstructured":"American Diabetes Association Professional Practice Committee 11. Chronic kidney disease and risk management: standards of care in diabetes \u2013 2024. Diabetes Care 47, S219\u2013S230 (2023).","journal-title":"Diabetes Care"},{"key":"1083_CR85","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.bone.2014.08.010","volume":"68","author":"ZN Zhu","year":"2014","unstructured":"Zhu, Z. N., Jiang, Y. F. & Ding, T. Risk of fracture with thiazolidinediones: an updated meta-analysis of randomized clinical trials. Bone 68, 115\u2013123 (2014).","journal-title":"Bone"},{"key":"1083_CR86","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/s41581-020-00367-2","volume":"17","author":"RZ Alicic","year":"2021","unstructured":"Alicic, R. Z., Cox, E. J., Neumiller, J. J. & Tuttle, K. R. Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence. Nat. Rev. Nephrol. 17, 227\u2013244 (2021).","journal-title":"Nat. Rev. Nephrol."},{"key":"1083_CR87","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.bone.2015.08.006","volume":"81","author":"M Pereira","year":"2015","unstructured":"Pereira, M. et al. Chronic administration of glucagon-like peptide-1 receptor agonists improves trabecular bone mass and architecture in ovariectomised mice. Bone 81, 459\u2013467 (2015).","journal-title":"Bone"},{"key":"1083_CR88","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.3168","volume":"35","author":"L Cheng","year":"2019","unstructured":"Cheng, L. et al. Glucagon-like peptide-1 receptor agonists and risk of bone fracture in patients with type 2 diabetes: a meta-analysis of randomized controlled trials. Diabetes Metab. Res. Rev. 35, e3168 (2019).","journal-title":"Diabetes Metab. Res. Rev."},{"key":"1083_CR89","doi-asserted-by":"crossref","first-page":"115197","DOI":"10.1016\/j.bone.2019.115197","volume":"132","author":"K Hygum","year":"2020","unstructured":"Hygum, K. et al. Bone resorption is unchanged by liraglutide in type 2 diabetes patients: a randomised controlled trial. Bone 132, 115197 (2020).","journal-title":"Bone"},{"key":"1083_CR90","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S2213-8587(20)30369-7","volume":"9","author":"DC Wheeler","year":"2021","unstructured":"Wheeler, D. C. et al. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 9, 22\u201331 (2021).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1083_CR91","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","volume":"396","author":"F Zannad","year":"2020","unstructured":"Zannad, F. et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet 396, 819\u2013829 (2020).","journal-title":"Lancet"},{"key":"1083_CR92","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/dom.12428","volume":"17","author":"B Bode","year":"2015","unstructured":"Bode, B. et al. Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes. Diabetes Obes. Metab. 17, 294\u2013303 (2015).","journal-title":"Diabetes Obes. Metab."},{"key":"1083_CR93","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1007\/s00125-019-4955-5","volume":"62","author":"Z Zhou","year":"2019","unstructured":"Zhou, Z. et al. Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS program. Diabetologia 62, 1854\u20131867 (2019).","journal-title":"Diabetologia"},{"key":"1083_CR94","volume":"35","author":"X Li","year":"2019","unstructured":"Li, X. et al. Effects of SGLT2 inhibitors on fractures and bone mineral density in type 2 diabetes: an updated meta-analysis. Diabetes Metab. Res. Rev. 35, e3170 (2019).","journal-title":"Diabetes Metab. Res. Rev."},{"key":"1083_CR95","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.diabet.2019.01.010","volume":"45","author":"L Cheng","year":"2019","unstructured":"Cheng, L. et al. Risk of bone fracture associated with sodium-glucose cotransporter-2 inhibitor treatment: a meta-analysis of randomized controlled trials. Diabetes Metab. 45, 436\u2013445 (2019).","journal-title":"Diabetes Metab."},{"key":"1083_CR96","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/ndt\/gfad185","volume":"39","author":"P Evenepoel","year":"2024","unstructured":"Evenepoel, P. et al. Recommended calcium intake in adults and children with chronic kidney disease \u2013 a European consensus statement. Nephrol. Dial. Transplant. 39, 341\u2013366 (2024).","journal-title":"Nephrol. Dial. Transplant."},{"key":"1083_CR97","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.cca.2019.11.040","volume":"502","author":"RB de Oliveira","year":"2020","unstructured":"de Oliveira, R. B., Stinghen, A. E. M. & Massy, Z. A. Vitamin K role in mineral and bone disorder of chronic kidney disease. Clin. Chim. Acta 502, 66\u201372 (2020).","journal-title":"Clin. Chim. Acta"},{"key":"1083_CR98","doi-asserted-by":"crossref","first-page":"1029475","DOI":"10.3389\/fendo.2022.1029475","volume":"13","author":"X Chang","year":"2022","unstructured":"Chang, X., Xu, S. & Zhang, H. Regulation of bone health through physical exercise: mechanisms and types. Front. Endocrinol. 13, 1029475 (2022).","journal-title":"Front. Endocrinol."},{"key":"1083_CR99","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12882-021-02289-y","volume":"22","author":"K Watanabe","year":"2021","unstructured":"Watanabe, K. et al. Home-based exercise and bone mineral density in peritoneal dialysis patients: a randomized pilot study. BMC Nephrol. 22, 98 (2021).","journal-title":"BMC Nephrol."},{"key":"1083_CR100","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1210\/er.2008-0002","volume":"29","author":"S Khosla","year":"2008","unstructured":"Khosla, S., Amin, S. & Orwoll, E. Osteoporosis in men. Endocr. Rev. 29, 441\u2013464 (2008).","journal-title":"Endocr. Rev."},{"key":"1083_CR101","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.tiv.2008.01.006","volume":"22","author":"A L\u00fche","year":"2008","unstructured":"L\u00fche, A. et al. Preclinical evidence for nitrogen-containing bisphosphonate inhibition of farnesyl diphosphate (FPP) synthase in the kidney: implications for renal safety. Toxicol. In Vitro 22, 899\u2013909 (2008).","journal-title":"Toxicol. In Vitro"},{"key":"1083_CR102","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/hdi.12773","volume":"23","author":"K Iseri","year":"2019","unstructured":"Iseri, K. et al. Elimination of intravenous alendronate by hemodialysis: a kinetic study. Hemodial. Int. 23, 466\u2013471 (2019).","journal-title":"Hemodial. Int."},{"key":"1083_CR103","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3109\/00365519609090584","volume":"56","author":"P Joffe","year":"1996","unstructured":"Joffe, P. & Henriksen, J. H. Aspects of osseous, peritoneal and renal handling of bisphosphonate during peritoneal dialysis: a methodological study. Scand. J. Clin. Lab. Invest. 56, 327\u2013337 (1996).","journal-title":"Scand. J. Clin. Lab. Invest."},{"key":"1083_CR104","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1002\/jbmr.4697","volume":"37","author":"R Eastell","year":"2022","unstructured":"Eastell, R. et al. Diabetes mellitus and the benefit of antiresorptive therapy on fracture risk. J. Bone Miner. Res. 37, 2121\u20132131 (2022).","journal-title":"J. Bone Miner. Res."},{"key":"1083_CR105","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1359\/JBMR.050817","volume":"20","author":"PD Miller","year":"2005","unstructured":"Miller, P. D. et al. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J. Bone Miner. Res. 20, 2105\u20132115 (2005).","journal-title":"J. Bone Miner. Res."},{"key":"1083_CR106","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1210\/jcem.85.11.6953","volume":"85","author":"DM Black","year":"2000","unstructured":"Black, D. M. et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J. Clin. Endocrinol. Metab. 85, 4118\u20134124 (2000).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1083_CR107","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1440-1797.2005.00436.x","volume":"10","author":"JB Wetmore","year":"2005","unstructured":"Wetmore, J. B., Benet, L. Z., Kleinstuck, D. & Frassetto, L. Effects of short-term alendronate on bone mineral density in haemodialysis patients. Nephrology 10, 393\u2013399 (2005).","journal-title":"Nephrology"},{"key":"1083_CR108","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/jbmr.3676","volume":"34","author":"K Iseri","year":"2019","unstructured":"Iseri, K. et al. Effects of denosumab and alendronate on bone health and vascular function in hemodialysis patients: a randomized, controlled trial. J. Bone Miner. Res. 34, 1014\u20131024 (2019).","journal-title":"J. Bone Miner. Res."},{"key":"1083_CR109","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.kint.2021.04.043","volume":"100","author":"M Haarhaus","year":"2021","unstructured":"Haarhaus, M. & Evenepoel, P. Differentiating the causes of adynamic bone in advanced chronic kidney disease informs osteoporosis treatment. Kidney Int. 100, 546\u2013558 (2021).","journal-title":"Kidney Int."},{"key":"1083_CR110","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.kint.2021.05.024","volume":"100","author":"SM Ott","year":"2021","unstructured":"Ott, S. M., Malluche, H. H., Jorgetti, V. & Elder, G. J. Importance of bone turnover for therapeutic decisions in patients with CKD-MBD. Kidney Int. 100, 502\u2013505 (2021).","journal-title":"Kidney Int."},{"key":"1083_CR111","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s11914-017-0361-4","volume":"15","author":"MR Allen","year":"2017","unstructured":"Allen, M. R. & Aref, M. W. What animal models have taught us about the safety and efficacy of bisphosphonates in chronic kidney disease. Curr. Osteoporos. Rep. 15, 171\u2013177 (2017).","journal-title":"Curr. Osteoporos. Rep."},{"key":"1083_CR112","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/sj.ki.5001899","volume":"70","author":"V Persy","year":"2006","unstructured":"Persy, V., De Broe, M. & Ketteler, M. Bisphosphonates prevent experimental vascular calcification: treat the bone to cure the vessels? Kidney Int. 70, 1537\u20131538 (2006).","journal-title":"Kidney Int."},{"key":"1083_CR113","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1002\/jbmr.3961","volume":"35","author":"D Alarkawi","year":"2020","unstructured":"Alarkawi, D. et al. Oral bisphosphonate use and all-cause mortality in patients with moderate-severe (grade 3B-5D) chronic kidney disease: a population-based cohort study. J. Bone Miner. Res. 35, 894\u2013900 (2020).","journal-title":"J. Bone Miner. Res."},{"key":"1083_CR114","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/jbmr.4235","volume":"36","author":"DE Robinson","year":"2021","unstructured":"Robinson, D. E. et al. Safety of oral bisphosphonates in moderate-to-severe chronic kidney disease: a binational cohort analysis. J. Bone Miner. Res. 36, 820\u2013832 (2021).","journal-title":"J. Bone Miner. Res."},{"key":"1083_CR115","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings, S. R. et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N. Engl. J. Med. 361, 756\u2013765 (2009).","journal-title":"N. Engl. J. Med."},{"key":"1083_CR116","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1210\/jc.2012-1569","volume":"97","author":"E Orwoll","year":"2012","unstructured":"Orwoll, E. et al. A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J. Clin. Endocrinol. Metab. 97, 3161\u20133169 (2012).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1083_CR117","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","volume":"5","author":"HG Bone","year":"2017","unstructured":"Bone, H. G. et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 5, 513\u2013523 (2017).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1083_CR118","doi-asserted-by":"crossref","first-page":"115268","DOI":"10.1016\/j.bone.2020.115268","volume":"134","author":"S Ferrari","year":"2020","unstructured":"Ferrari, S. et al. Denosumab in postmenopausal women with osteoporosis and diabetes: subgroup analysis of FREEDOM and FREEDOM extension. Bone 134, 115268 (2020).","journal-title":"Bone"},{"key":"1083_CR119","volume":"381","author":"H Lyu","year":"2023","unstructured":"Lyu, H. et al. Denosumab and incidence of type 2 diabetes among adults with osteoporosis: population based cohort study. BMJ 381, e073435 (2023).","journal-title":"BMJ"},{"key":"1083_CR120","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nm.3084","volume":"19","author":"S Kiechl","year":"2013","unstructured":"Kiechl, S. et al. Blockade of receptor activator of nuclear factor-\u03baB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus. Nat. Med. 19, 358\u2013363 (2013).","journal-title":"Nat. Med."},{"key":"1083_CR121","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.cmet.2015.05.021","volume":"22","author":"NG Kondegowda","year":"2015","unstructured":"Kondegowda, N. G. et al. Osteoprotegerin and denosumab stimulate human beta cell proliferation through inhibition of the receptor activator of NF-\u03baB ligand pathway. Cell Metab. 22, 77\u201385 (2015).","journal-title":"Cell Metab."},{"key":"1083_CR122","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1002\/jbmr.403","volume":"26","author":"SA Jamal","year":"2011","unstructured":"Jamal, S. A. et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. J. Bone Miner. Res. 26, 1829\u20131835 (2011).","journal-title":"J. Bone Miner. Res."},{"key":"1083_CR123","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1007\/s00198-018-4533-6","volume":"29","author":"C Thongprayoon","year":"2018","unstructured":"Thongprayoon, C. et al. Hypocalcemia and bone mineral density changes following denosumab treatment in end-stage renal disease patients: a meta-analysis of observational studies. Osteoporos. Int. 29, 1737\u20131745 (2018).","journal-title":"Osteoporos. Int."},{"key":"1083_CR124","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1001\/jama.2023.28239","volume":"331","author":"ST Bird","year":"2024","unstructured":"Bird, S. T. et al. Severe hypocalcemia with denosumab among older female dialysis-dependent patients. JAMA 331, 491\u2013499 (2024).","journal-title":"JAMA"},{"key":"1083_CR125","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000380960","volume":"41","author":"V Dave","year":"2015","unstructured":"Dave, V., Chiang, C. Y., Booth, J. & Mount, P. F. Hypocalcemia post denosumab in patients with chronic kidney disease stage 4-5. Am. J. Nephrol. 41, 129\u2013137 (2015).","journal-title":"Am. J. Nephrol."},{"key":"1083_CR126","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/humrep\/dew027","volume":"31","author":"L Webber","year":"2016","unstructured":"Webber, L. et al. ESHRE guideline: management of women with premature ovarian insufficiency. Hum. Reprod. 31, 926\u2013937 (2016).","journal-title":"Hum. Reprod."},{"key":"1083_CR127","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1093\/ndt\/14.5.1238","volume":"14","author":"J Matuszkiewicz-Rowinska","year":"1999","unstructured":"Matuszkiewicz-Rowinska, J. et al. The benefits of hormone replacement therapy in pre-menopausal women with oestrogen deficiency on haemodialysis. Nephrol. Dial. Transplant. 14, 1238\u20131243 (1999).","journal-title":"Nephrol. Dial. Transplant."},{"key":"1083_CR128","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1001\/jama.2013.278040","volume":"310","author":"JE Manson","year":"2013","unstructured":"Manson, J. E. et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women\u2019s Health Initiative randomized trials. JAMA 310, 1353\u20131368 (2013).","journal-title":"JAMA"},{"key":"1083_CR129","first-page":"Cd002229","volume":"2015","author":"HM Boardman","year":"2015","unstructured":"Boardman, H. M. et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst. Rev. 2015, Cd002229 (2015).","journal-title":"Cochrane Database Syst. Rev."},{"key":"1083_CR130","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1097\/GME.0000000000000296","volume":"21","author":"M Canonico","year":"2014","unstructured":"Canonico, M. Hormone therapy and hemostasis among postmenopausal women: a review. Menopause 21, 753\u2013762 (2014).","journal-title":"Menopause"},{"key":"1083_CR131","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1210\/jcem.87.8.8750","volume":"87","author":"PD Delmas","year":"2002","unstructured":"Delmas, P. D. et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J. Clin. Endocrinol. Metab. 87, 3609\u20133617 (2002).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1083_CR132","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1080\/cmt.4.4.320.331","volume":"4","author":"T Nickelsen","year":"2001","unstructured":"Nickelsen, T. et al. Differential effects of raloxifene and continuous combined hormone replacement therapy on biochemical markers of cardiovascular risk: results from the Euralox 1 study. Climacteric 4, 320\u2013331 (2001).","journal-title":"Climacteric"},{"key":"1083_CR133","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1681\/ASN.2007050555","volume":"19","author":"A Ishani","year":"2008","unstructured":"Ishani, A., Blackwell, T., Jamal, S. A., Cummings, S. R. & Ensrud, K. E. The effect of raloxifene treatment in postmenopausal women with CKD. J. Am. Soc. Nephrol. 19, 1430\u20131438 (2008).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1083_CR134","first-page":"461","volume":"8","author":"F Haghverdi","year":"2014","unstructured":"Haghverdi, F., Mortaji, S., Soltani, P., Saidi, N. & Farbodara, T. Effect of raloxifene on parathyroid hormone in osteopenic and osteoporotic postmenopausal women with chronic kidney disease stage 5. Iran. J. Kidney Dis. 8, 461\u2013466 (2014).","journal-title":"Iran. J. Kidney Dis."},{"key":"1083_CR135","doi-asserted-by":"crossref","first-page":"464","DOI":"10.5812\/ijem.3794","volume":"10","author":"O Saito","year":"2012","unstructured":"Saito, O. et al. Effects of raloxifene on bone metabolism in hemodialysis patients with type 2 diabetes. Int. J. Endocrinol. Metab. 10, 464\u2013469 (2012).","journal-title":"Int. J. Endocrinol. Metab."},{"key":"1083_CR136","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1007\/s11914-018-0483-3","volume":"16","author":"J Aleksova","year":"2018","unstructured":"Aleksova, J. et al. Gonadal hormones in the pathogenesis and treatment of bone health in patients with chronic kidney disease: a systematic review and meta-analysis. Curr. Osteoporos. Rep. 16, 674\u2013692 (2018).","journal-title":"Curr. Osteoporos. Rep."},{"key":"1083_CR137","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3109\/13697137.2013.830605","volume":"17","author":"S Adami","year":"2014","unstructured":"Adami, S. et al. The efficacy and safety of bazedoxifene in postmenopausal women by baseline kidney function status. Climacteric 17, 273\u2013284 (2014).","journal-title":"Climacteric"},{"key":"1083_CR138","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1210\/jc.2018-00229","volume":"103","author":"S Bhasin","year":"2018","unstructured":"Bhasin, S. et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 103, 1715\u20131744 (2018).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1083_CR139","doi-asserted-by":"crossref","first-page":"5462","DOI":"10.1210\/jc.2004-0804","volume":"89","author":"S Dhindsa","year":"2004","unstructured":"Dhindsa, S. et al. Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. J. Clin. Endocrinol. Metab. 89, 5462\u20135468 (2004).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1083_CR140","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1210\/jc.2007-2177","volume":"93","author":"M Grossmann","year":"2008","unstructured":"Grossmann, M. et al. Low testosterone levels are common and associated with insulin resistance in men with diabetes. J. Clin. Endocrinol. Metab. 93, 1834\u20131840 (2008).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1083_CR141","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1210\/jc.2011-0118","volume":"96","author":"M Grossmann","year":"2011","unstructured":"Grossmann, M. Low testosterone in men with type 2 diabetes: significance and treatment. J. Clin. Endocrinol. Metab. 96, 2341\u20132353 (2011).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1083_CR142","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S2213-8587(20)30367-3","volume":"9","author":"G Wittert","year":"2021","unstructured":"Wittert, G. et al. Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial. Lancet Diabetes Endocrinol. 9, 32\u201345 (2021).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1083_CR143","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1093\/ndt\/gfq397","volume":"26","author":"JJ Carrero","year":"2011","unstructured":"Carrero, J. J. et al. Prevalence and clinical implications of testosterone deficiency in men with end-stage renal disease. Nephrol. Dial. Transplant. 26, 184\u2013190 (2011).","journal-title":"Nephrol. Dial. Transplant."},{"key":"1083_CR144","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1002\/j.1939-4640.2004.tb02851.x","volume":"25","author":"S Guvel","year":"2004","unstructured":"Guvel, S. et al. Calcification of the epididymis and the tunica albuginea of the corpora cavernosa in patients on maintenance hemodialysis. J. Androl. 25, 752\u2013756 (2004).","journal-title":"J. Androl."},{"key":"1083_CR145","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/ki.1997.109","volume":"51","author":"L Dunkel","year":"1997","unstructured":"Dunkel, L., Raivio, T., Laine, J. & Holmberg, C. Circulating luteinizing hormone receptor inhibitor(s) in boys with chronic renal failure. Kidney Int. 51, 777\u2013784 (1997).","journal-title":"Kidney Int."},{"key":"1083_CR146","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1053\/j.ajkd.2005.10.022","volume":"47","author":"AT Brockenbrough","year":"2006","unstructured":"Brockenbrough, A. T. et al. Transdermal androgen therapy to augment EPO in the treatment of anemia of chronic renal disease. Am. J. Kidney Dis. 47, 251\u2013262 (2006).","journal-title":"Am. J. Kidney Dis."},{"key":"1083_CR147","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"RM Neer","year":"2001","unstructured":"Neer, R. M. et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 344, 1434\u20131441 (2001).","journal-title":"N. Engl. J. Med."},{"key":"1083_CR148","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s00198-004-1713-3","volume":"16","author":"JM Kaufman","year":"2005","unstructured":"Kaufman, J. M. et al. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos. Int. 16, 510\u2013516 (2005).","journal-title":"Osteoporos. Int."},{"key":"1083_CR149","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00223-010-9424-6","volume":"87","author":"J Satterwhite","year":"2010","unstructured":"Satterwhite, J. et al. Pharmacokinetics of teriparatide (rhPTH[1-34]) and calcium pharmacodynamics in postmenopausal women with osteoporosis. Calcif. Tissue Int. 87, 485\u2013492 (2010).","journal-title":"Calcif. Tissue Int."},{"key":"1083_CR150","doi-asserted-by":"crossref","first-page":"166","DOI":"10.5414\/CP202001","volume":"52","author":"H Imai","year":"2014","unstructured":"Imai, H. et al. Pharmacokinetics of teriparatide after subcutaneous administration to volunteers with renal failure: a pilot study. Int. J. Clin. Pharmacol. Ther. 52, 166\u2013174 (2014).","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"1083_CR151","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1007\/s00198-021-05975-7","volume":"32","author":"P Evenepoel","year":"2021","unstructured":"Evenepoel, P. et al. Diagnosis and management of osteoporosis in chronic kidney disease stages 4 to 5D: a call for a shift from nihilism to pragmatism. Osteoporos. Int. 32, 2397\u20132405 (2021).","journal-title":"Osteoporos. Int."},{"key":"1083_CR152","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.bone.2016.06.017","volume":"91","author":"AV Schwartz","year":"2016","unstructured":"Schwartz, A. V. et al. Teriparatide in patients with osteoporosis and type 2 diabetes. Bone 91, 152\u2013158 (2016).","journal-title":"Bone"},{"key":"1083_CR153","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.2147\/CIA.S120175","volume":"11","author":"A Nishikawa","year":"2016","unstructured":"Nishikawa, A., Yoshiki, F., Taketsuna, M., Kajimoto, K. & Enomoto, H. Safety and effectiveness of daily teriparatide for osteoporosis in patients with severe stages of chronic kidney disease: post hoc analysis of a postmarketing observational study. Clin. Interv. Aging 11, 1653\u20131659 (2016).","journal-title":"Clin. Interv. Aging"},{"key":"1083_CR154","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1007\/s00198-015-3377-6","volume":"27","author":"K Sumida","year":"2016","unstructured":"Sumida, K. et al. Once-weekly teriparatide in hemodialysis patients with hypoparathyroidism and low bone mass: a prospective study. Osteoporos. Int. 27, 1441\u20131450 (2016).","journal-title":"Osteoporos. Int."},{"key":"1083_CR155","doi-asserted-by":"crossref","first-page":"5496710","DOI":"10.1155\/2019\/5496710","volume":"2019","author":"K Kritmetapak","year":"2019","unstructured":"Kritmetapak, K. & Pongchaiyakul, C. Parathyroid hormone measurement in chronic kidney disease: from basics to clinical implications. Int. J. Nephrol. 2019, 5496710 (2019).","journal-title":"Int. J. Nephrol."},{"key":"1083_CR156","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000316708","volume":"33","author":"D Cejka","year":"2010","unstructured":"Cejka, D., Kodras, K., Bader, T. & Haas, M. Treatment of hemodialysis-associated adynamic bone disease with teriparatide (PTH1-34): a pilot study. Kidney Blood Press. Res. 33, 221\u2013226 (2010).","journal-title":"Kidney Blood Press. Res."},{"key":"1083_CR157","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00198-006-0189-8","volume":"18","author":"PD Miller","year":"2007","unstructured":"Miller, P. D., Schwartz, E. N., Chen, P., Misurski, D. A. & Krege, J. H. Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporos. Int. 18, 59\u201368 (2007).","journal-title":"Osteoporos. Int."},{"key":"1083_CR158","doi-asserted-by":"crossref","first-page":"219","DOI":"10.5414\/CN110993","volume":"98","author":"HH Malluche","year":"2022","unstructured":"Malluche, H. H., Davenport, D. L., Monier-Faugere, M. C. & Lima, F. Treatment of bone loss in CKD5D: better survival in patients with non-high bone turnover. Clin. Nephrol. 98, 219\u2013228 (2022).","journal-title":"Clin. Nephrol."},{"key":"1083_CR159","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","volume":"316","author":"PD Miller","year":"2016","unstructured":"Miller, P. D. et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA 316, 722\u2013733 (2016).","journal-title":"JAMA"},{"key":"1083_CR160","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1080\/03007995.2019.1656955","volume":"35","author":"JP Bilezikian","year":"2019","unstructured":"Bilezikian, J. P. et al. Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial. Curr. Med. Res. Opin. 35, 2097\u20132102 (2019).","journal-title":"Curr. Med. Res. Opin."},{"key":"1083_CR161","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman, F. et al. Romosozumab treatment in postmenopausal women with osteoporosis. N. Engl. J. Med. 375, 1532\u20131543 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1083_CR162","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1002\/jcph.2050","volume":"62","author":"CP Hsu","year":"2022","unstructured":"Hsu, C. P., Maddox, J., Block, G., Bartley, Y. & Yu, Z. Influence of renal function on pharmacokinetics, pharmacodynamics, and safety of a single dose of romosozumab. J. Clin. Pharmacol. 62, 1132\u20131141 (2022).","journal-title":"J. Clin. Pharmacol."},{"issue":"Suppl. 1","key":"1083_CR163","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1136\/annrheumdis-2020-eular.4539","volume":"79","author":"P Miller","year":"2020","unstructured":"Miller, P. et al. Efficacy and safety of romosozumab among postmenopausal women with osteoporosis and mild-to-moderate chronic kidney disease [abstract OP0297]. Ann. Rheum. Dis. 79 (Suppl. 1), 185 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"1083_CR164","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1007\/s00774-021-01253-y","volume":"39","author":"M Sato","year":"2021","unstructured":"Sato, M. et al. Efficacy of romosozumab in patients with osteoporosis on maintenance hemodialysis in Japan; an observational study. J. Bone Miner. Metab. 39, 1082\u20131090 (2021).","journal-title":"J. Bone Miner. Metab."},{"key":"1083_CR165","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s00223-022-01031-6","volume":"112","author":"T Saito","year":"2023","unstructured":"Saito, T. et al. One-year romosozumab treatment followed by one-year denosumab treatment for osteoporosis in patients on hemodialysis: an observational study. Calcif. Tissue Int. 112, 34\u201344 (2023).","journal-title":"Calcif. Tissue Int."},{"key":"1083_CR166","first-page":"195","volume":"378","author":"KG Saag","year":"2018","unstructured":"Saag, K. G., Petersen, J. & Grauer, A. Romosozumab versus alendronate and fracture risk in women with osteoporosis. N. Engl. J. Med. 378, 195\u2013196 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1083_CR167","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1210\/jc.2017-02163","volume":"103","author":"EM Lewiecki","year":"2018","unstructured":"Lewiecki, E. M. et al. A phase III randomized placebo-controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis. J. Clin. Endocrinol. Metab. 103, 3183\u20133193 (2018).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1083_CR168","doi-asserted-by":"crossref","first-page":"eaay6570","DOI":"10.1126\/scitranslmed.aay6570","volume":"12","author":"J Bovijn","year":"2020","unstructured":"Bovijn, J. et al. Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics. Sci. Transl. Med. 12, eaay6570 (2020).","journal-title":"Sci. Transl. Med."},{"key":"1083_CR169","doi-asserted-by":"crossref","first-page":"16001","DOI":"10.1038\/boneres.2016.1","volume":"4","author":"MR Rubin","year":"2016","unstructured":"Rubin, M. R. & Patsch, J. M. Assessment of bone turnover and bone quality in type 2 diabetic bone disease: current concepts and future directions. Bone Res. 4, 16001 (2016).","journal-title":"Bone Res."}],"container-title":["Nature Reviews Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41574-024-01083-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41574-024-01083-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41574-024-01083-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T12:02:40Z","timestamp":1744632160000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41574-024-01083-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,16]]},"references-count":169,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["1083"],"URL":"https:\/\/doi.org\/10.1038\/s41574-024-01083-8","relation":{},"ISSN":["1759-5029","1759-5037"],"issn-type":[{"value":"1759-5029","type":"print"},{"value":"1759-5037","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,16]]},"assertion":[{"value":"16 December 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.E. has received funding from Amgen, Alexion and Sanofi, and honoraria from Amgen, Alexion and Kyowa Kirin. J.A. and G.E. declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}